WO2019078558A1 - Composition, for preventing or treating diabetes and obesity, comprising lactobacillus sakei probio-65 or extract thereof - Google Patents

Abstract

The present invention provides a composition, for preventing or treating diabetes and obesity, comprising lactobacillus sakei probio-65 as an active ingredient. The present invention provides a composition, which comprises lactobacillus sakei probio-65 or an extract thereof and is for preventing or treating diabetes and obesity, which does not show side effects, has antidiabetic effects, and also allows enhanced lipid metabolism and sugar metabolism and thus enables prevention or treatment of obesity.

Description

Composition for preventing or treating diabetes and obesity comprising Lactobacillus saccharide PROBIO-65 or an extract thereof

The present invention relates to a composition for preventing or treating diabetes and obesity, which comprises Lactobacillus casei Probio-65 or an extract thereof. More specifically, the present invention relates to a composition for preventing or treating diabetes and obesity, which has no side effects and has lipid metabolism and glucose metabolism And a composition for preventing or treating diabetes and obesity comprising Lactobacillus casei Probio-65 or an extract thereof which is capable of preventing or treating obesity.

Probio-65 (Lactobacillus sakei Probio-65) is a strain isolated from kimchi, a fermented food traditionally secured by Koreans for hundreds of years. Lactobacillus casei Probio-64 exhibits acid resistance, biliary and antibiotic resistance, suppresses the growth of harmful pathogenic microorganisms in the body and intestines of animals, exhibits immunity-enhancing activity, and is a disease-exacerbating factor of atopic dermatitis It is effective for the treatment or prevention of atopic dermatitis by inhibiting the growth of Staphylococcus aureus, which is known, and is also effective for the treatment or prevention of allergy-related diseases, suppresses abnormal proliferation of intestinal harmful microorganisms, . ≪ / RTI >

The inventors of the present invention have proposed Lactobacillus casei Probio-65 and its composition as an inventor of Korean Patent No. 10-0479719. The present inventor has found that Lactobacillus casei Probio-65 or an extract thereof can be used as a composition for the prevention or treatment of diabetes or obesity while conducting research on other efficacy of Lactobacillus casei Probio-65.

Diabetic (Diabetic mellitus) is a representative adult disease that means long-term metabolic disease in which hyperglycemia lasts for a long time. Hyperglycemia symptoms lead to severe thirst and hunger, frequent urination, and serious complications if not treated. There are two types of diabetes. Insulin Dependent Diabetes Mellitus (IDDM) is caused by a deficiency of insulin secretion, a glucose-regulating hormone in the blood, and is called pediatric diabetes because it occurs mainly in young people between the ages of 10 and 20. In addition, type 2 diabetes (Noninsulin Dependent Diabetes Mellitus) occurs mainly after the age of 40 and accounts for the majority of people with diabetes in Korea. Unlike type Ⅰ diabetes, it is called adult type diabetes and the cause of the disease is not clear yet, but it is known that genetic factors and environmental factors are involved together.

Diabetic peripheral neuropathy, which is the most common complication of diabetes, begins to show its symptoms in about 50% of diabetes progressed over 10 years. The initial symptoms start with the hands, especially the senses of the feet, and persist in severe pain, resulting in loss of sensory and peripheral autonomic nerve damage and blood flow disorders. Further progression may result in painless ulceration and infection, severely impaired limb amputation, and acute complications that can lead to sepsis and lead to life-threatening complications.

The mechanism of the development of diabetic peripheral neuropathy is still unclear despite many studies. There is no treatment for various diabetic complications, including peripheral neuropathy, ultimately. Although active glycemic control and elimination of risk factors such as hyperlipidemia, hypercholesterolemia, overweight, smoking and drinking are known to prevent or delay the occurrence of complications to a certain extent, there is currently no drug available to treat complications that have occurred. Currently, diabetic agents such as sulfonylurea, metformin, alpha glucosidase inhibitor, thiazolidinedione, and meglitinide are used, but they have side effects such as hypoglycemia, arthritis, digestive disorder, edema and heart failure have.

In addition, obesity is a metabolic disease caused by unbalance of intake and consumption of calories. Generally, the obesity is controlled so that the consumption of calories exceeds the consumption or the consumption of the calories consumed is higher than that of the calories consumed. Exercise can treat obesity symptoms. However, obesity, which is difficult to treat, should be treated with obesity treatment. To date, obesity treatments have been used as appetite suppressants by Reductil (USA), Xenical (Roche Pharmaceuticals, Switzerland), Contrave (Oxygen Therapeutics, USA) . However, the above-mentioned obesity therapeutic agents have various side effects and low persistency of efficacy.

Recently, there have been many attempts to prevent and treat diabetes by reducing blood cholesterol levels by using biocompatible lactic acid bacteria without side effects. Especially, lactic acid bacteria extracted from kimchi are reported to have immune control, immune enhancement, antimicrobial, antioxidant, anti-cancer effect, anti-obesity effect, prevention of hypertension and constipation prevention effect. However, lactic acid bacteria-related technology having excellent antidiabetic or anti-obesity effect which is commercially available is not reported.

The technical problem of the present invention is to provide a method for preventing or treating obesity, which has no side effects, has an anti-diabetic effect, and can improve lipid metabolism and glucose metabolism, and is useful for the treatment or prevention of diabetes or obesity including Lactobacillus casei Probio- Prevention or treatment of cancer.

The above and other objects of the present invention can be achieved by the present invention described below.

The composition for preventing or treating diabetes and obesity comprising Lactobacillus casei Probio-65 or an extract thereof according to the present invention is characterized by containing Lactobacillus casei Probio-65 as an active ingredient.

Here, the Lactobacillus casei probio-65 is a Lactobacillus casei Probio-65 culture obtained by liquid-culturing a Lactobacillus casei Probio-65 strain.

The Lactobacillus casei Probio-65 is a powder cell in which the Lactobacillus casei Probio-65 strain, in which Lactobacillus casei Probio-65 strain was liquid-cultured, was dried or spray dried to remove moisture.

The Lactobacillus casei Probio-65 was prepared by extracting Lactobacillus casei Probio-65 culture liquid of Lactobacillus casei Probio-65 strain, which was filtered, and then concentrated under reduced pressure to obtain Lactobacillus casei Probio-65 .

The above-mentioned Lactobacillus casei probiote 65 was prepared by extracting Lactobacillus casei Probio-65 culture broth obtained by liquid culture of Lactobacillus casei Probio-65 strain, filtering it, and extracting the Lactobacillus casei Probio-65 culture solution under reduced pressure Characterized in that it is a powder of Lactobacillus casei Probio-65 culture solution obtained by freeze-drying or spray-drying to remove water and pulverization.

The present invention has no side effects, has anti-diabetic effect, improves lipid metabolism and glucose metabolism, can prevent or treat obesity, and is not a viable lactic acid bacteria having viability. Therefore, The present invention has the effect of providing a composition for the prevention or treatment of diabetes and obesity, which comprises an easy Lactobacillus casei Probio-65 or an extract thereof.

FIG. 1 is a graph showing changes in blood glucose level after 7 weeks of normal control, diabetic control, diabetes treatment control (Pioglitozone), diabetes treatment group (SEL001), and strain administration group (Live cell).

FIG. 2 is a graph showing blood glucose changes after 1 week and 7 weeks in a normal control, a diabetic control, a diabetes control group (Pioglitozone), a diabetes treatment group (SEL001), and a live cell group.

FIG. 3 is a graph showing the oral administration effect of the extract of Lactobacillus casei Probio-65 on total cholesterol after 7 weeks of the experiment.

FIG. 4 is a graph showing the oral administration effect of the extract of Lactobacillus casei Probio-65 on Triglycereide after 7 weeks of the experiment.

FIG. 5 is a graph showing the oral administration effect of the extract of Lactobacillus casei Probio-65 on HDL-cholesterol content (HDL) after 7 weeks of the experiment.

FIG. 6 is a graph showing the oral administration effect of the extract of Lactobacillus casei Probio-65 on LDL-cholesterol content (LDL) after 7 weeks of the experiment.

FIG. 7 is a graph showing changes in body weight for 10 weeks in a normal control, an HFD control, an obesity treatment control group (Orlistat), an obesity treatment group (SEL001), and a live cell group.

FIG. 8 is a graph showing weight gain after 10 weeks of a normal control, an HFD control, an obesity treatment group (Orlistat), an obesity treatment group (SEL001), and a live cell group.

FIG. 9 is a graph showing the oral administration effect of the extract of Lactobacillus casei Probio-65 on total cholesterol after 10 weeks of the experiment.

FIG. 10 is a graph showing the oral administration effect of an extract of Lactobacillus casei Probio-65 on triglyceride 10 weeks after the experiment.

FIG. 11 is a graph showing the oral administration effect of the extract of Lactobacillus casei Probio-65 on HDL-cholesterol content (HDL) 10 weeks after the experiment.

FIG. 12 is a graph showing the oral administration effect of an extract of Lactobacillus casei Probio-65 on LDL-cholesterol content (LDL) 10 weeks after the experiment.

13 is a graph showing the oral administration effect of the extract of Lactobacillus casei Probio-65 on leptin content.

14 is a graph showing the oral administration effect of the extract of Lactobacillus casei Probio-65 on the adiponectin content.

15 is a graph showing the oral administration effect of the extract of Lactobacillus casei Probio-65 on the content of ricin;

FIG. 16 is a graph showing the oral administration effect of the extract of Lactobacillus casei Probio-65 on the IL-1β content. FIG.

17 is a graph showing the oral administration effect of the extract of Lactobacillus casei Probio-65 on the IL-6 content.

The above-mentioned objects, features and advantages of the present invention will become more apparent by describing in detail preferred embodiments and comparative examples of the present invention. The following detailed description is not to be taken in a limiting sense, and the scope of the invention is to be limited only by the appended claims, along with the full scope of equivalents to which the claims are entitled.

Hereinafter, the present invention will be described in more detail with reference to the accompanying drawings and embodiments.

Example

Example  One: Lactobacillus Sakai Probio -65 culture medium preparation

Lactobacillus casei Probio-65 isolated from Kimchi, a traditional Korean fermented food, was cultured in MRS broth (Difco laboratories, USA) for 15 hours at 37 ℃ for 15 hours to improve the physiological activity of long- After incubation for 2-3 times, the obtained supernatant was used as a starter using the MRS broth medium and cultured for 15 hours at 37 ° C in a constant temperature incubator. Then, 1% by weight of glucose, 1% by weight of yeast extract, 0.25% by weight of soap peptone, 0.1% by weight of polyoxyethelene sorbitan mono-oleate, ammonium sulfate ((NH ₄ ) ₂ SO ₄ ), 0.1% by weight of magnesium sulfate (MgSO ₄ ), 0.01% by weight of magnesium sulfate (MgSO ₄ ), 0.1% by weight of potassium dihydrogen phosphate (KH ₂ PO ₄ ) and 90-99% by weight of water was sterilized at 121 ° C for 15 minutes , And this Lactobacillus casei Probio65 was cultured in a 2 L flask by liquid culture at 37 DEG C for 24 hours using this medium.

Example  2: Lactobacillus Sakai Probio -65 Preparation of culture extract powder

500 ml of 95 wt% ethanol (DUKSAN, Korea) was added to 500 ml of Lactobacillus casei Probio-65 culture, and the mixture was stirred at 25 ° C for 6 hours at 140 rpm to extract the inner material of the strain. The extract was filtered and concentrated under reduced pressure to separate the ethanol and the extract. The separated extract was lyophilized for 64 hours using a freeze dryer (Ilshin Lab, Korea) to obtain Lactobacillus casei Probio-65 culture solution ethanol extract powder (Hereinafter referred to as 'extract').

Example  3: Using animal models Lactobacillus Sakai Probio -65 < / RTI > Anti-diabetic  Effect experiment

Example 3-1 Experimental animal breeding

The experimental animals were 4 weeks old ICR male mice with an average body weight of 35 ± 3.0 g and 42 rats were purchased for each of 6 rats in each experimental group. The rats were housed at room temperature 23 ± 2 ℃, humidity 60 ± 5% In order to adapt to the environmental conditions, the animals were preliminarily fed for 1 week with a general diet (Central Lab. Animal Inc., Korea) purchased from a central laboratory animal.

Example 3-2 Diabetic induction in normal rats

Mice were fed a 60% high-fat diet (HFD) for several weeks to induce diabetes by insulin resistance or glucose hypersensitivity. Diabetes was induced by ingestion of streptozotocin (STZ 50 mg / kg) once or several times. The mice were fasted one day before induction with STZ. Diabetic-induced mice received HFD for a total study period of 7 weeks. Diabetes induction was confirmed by examining fasting blood glucose levels.

Example 3-3 Classification of experiment group

Diabetic control (diabetic control) fed with normal diet after diabetic induction and pioglitazone, a diabetic therapeutic substance, as a control group for diabetes treatment were administered 10 mg / kg of normal control (Pioglitozone) or diabetic treatment after diabetic induction, Lactobacillus casei Probio-65 culture solution prepared in Example 2 was lyophilized to prepare powder, (SEL001 (50 mg / kg)) and Lactobacillus probi-65 strain (Live cell (10 ^ 8)) were orally administered at a concentration of 50 mg / . Diabetic therapy Pioglitazone, used in the control group, is known to induce hypoglycemic function by increasing the sensitivity of insulin to thiazolidinedione drugs.

Example 3-4 Measurement of Post-meal Blood Glucose Change

The postprandial changes in blood sugar were measured for the 7 groups of the above experimental groups. Specifically, the postprandial changes in blood glucose during the rearing period were measured once a week, two hours after the meal, and the blood of the tail vein was collected and measured with a glucose meter (ACCU-CHEK sensor, Germany).

FIG. 1 is a graph showing changes in blood glucose level after 7 weeks of normal control, diabetic control, diabetes treatment control (Pioglitozone), diabetes treatment group (SEL001), and strain administration group (Live cell). The concrete data of FIG. 1 is shown in Table 1 below.

Table 1

As can be seen in FIG. 1 and Table 1, in the normal control group, blood glucose was changed in the range of 128 ~ 170.33 ㎎ / dl during the 7 weeks of experiment. Diabetic control was 434.67 ㎎ / ㎗ at 368.67 ㎎ / ㎗, respectively. However, in the diabetes treatment group (SEL001) of the present invention, the blood glucose level decreased from 399.83 mg / dl to 209.17 mg / dl, confirming that the diabetes treatment effect was similar to the diabetes treatment control group (Pioglitozone) cell of the present invention had a reduced blood sugar level at the 7th week when compared to the diabetic control. Therefore, the composition containing the active ingredient of Lactobacillus casei Probio-65 of the present invention according to the diabetes treatment group (SEL001) and the strain group (Live cell) Was effective in the treatment and prevention of diabetes mellitus.

FIG. 2 is a graph showing blood glucose changes after 1 week and 7 weeks in a normal control, a diabetic control, a diabetes control group (Pioglitozone), a diabetes treatment group (SEL001), and a live cell group. As can be seen from FIG. 2, the blood glucose levels of the normal control, diabetic control, diabetes control group (Pioglitozone), diabetes treatment group (SEL001) and the strain group (Live cell) 128.33 respectively; 390.67; 295.17; 313.67; The blood glucose levels of normal control, diabetic control, diabetes control group (Pioglitozone), diabetes treatment group (SEL001) and live cell group were found to be 153.58 mg / dl and 270.33 mg / dl, respectively. 434.67; 208.50; 209.17; 287.00 mg / ㎗. In the diabetes treatment group (SEL001), the decrease in the blood glucose level in the diabetes control group (Pioglitozone) was confirmed.

After 7 weeks of breeding, mice fasted for 12 hours were anesthetized with ether and dissected. Blood was collected from the abdominal vein using a heparinized syringe. After blood collection, the blood was left for 30 minutes and centrifuged at 3,000 rpm for 15 minutes to separate plasma. The separated plasma was quenched with liquid nitrogen and stored at -80 ° C until analysis. Total cholesterol, triglyceride, high density lipoprotein (HDL) - cholesterol content (HDL) and LDL (low density lipoprotein) - cholesterol content (HDL) were analyzed using a blood analyzer .

FIG. 3 is a graph showing the oral administration effect of the extract of Lactobacillus casei Probio-65 on total cholesterol after 7 weeks of the experiment.

As shown in FIG. 3, the diabetic control value was 301.79 mg / dl. However, the diabetes treatment group (SEL001) and the live cell group of the present invention significantly decreased the total cholesterol level, And the total cholesterol-lowering effect similar to that of the control (Pioglitozone) was confirmed.

FIG. 4 is a graph showing the oral administration effect of the extract of Lactobacillus casei Probio-65 on Triglycereide after 7 weeks of the experiment.

As shown in FIG. 4, the Plasma Triglyceride (TG) value of the diabetic control was the highest at 1.59 mol / l, but in the normal control in which the low-fat diet (LFD) Was measured to be 0.95 mol / l. However, the diabetes treatment group (SEL001) and the live cell of the present invention were measured to have lower TG than the normal control group. This means that the diabetes treatment group (SEL001) and the live cell group have an effect of reducing TG in HFD-STZ-induced mice such as diabetes control group (Pioglitozone).

FIG. 5 is a graph showing the oral administration effect of the extract of Lactobacillus casei Probio-65 on HDL-cholesterol content (HDL) after 7 weeks of experiment. FIG. This is a graph showing the oral administration effect of the extract of Bacillus sakie Probio-65.

As can be seen from FIG. 5 and FIG. 6, the high-density lipoprotein (HDL) was decreased in the diabetic control group as compared with the normal control group. In contrast, the HDL levels of the diabetes control (Pioglitozone), diabetes treatment group (SEL001) and strain (Live cell) were as high as 41.00 mg / dL, 45.52 mg / dL and 42.55 mg / dL, respectively. This indicates that the HDL of the diabetic control is decreased due to diabetes induction and the HDL is increased due to the treatment of the diabetes treatment control group (Pioglitozone), diabetes treatment group (SEL001) or the live cell group (Live cell). In addition, low-density lipoprotein (LDL) was increased in the diabetic control compared to the normal control, and after treatment of the diabetes control group (Pioglitozone), diabetes treatment group (SEL001) LDL levels decreased.

Example  4: Using animal models Lactobacillus Sakai Probio -65 and obesity effect test of extract

Example 4-1 Experimental animal breeding

Experimental animals were 4-week-old ICR male mice with an average body weight of 35 ± 3.0 g. Forty-two mice were purchased for each of the experimental groups. The animals were housed at room temperature 23 ± 2 ℃, humidity 60 ± 5% For the adaptation, the animals were pre-fed for 1 week with the general diet purchased from the central laboratory animal (Central Lab. Animal Inc., Korea) and then subjected to the experiment for 10 weeks.

Example 4-2 Obesity induction in normal rats

For obesity induction, the mice were fed a 60% High-Fat Diet (HFD) for 6 weeks.

4-3 Classification of experiment group

In the experimental group, the control group (normal control) fed with normal diet, the obesity control group (HFD Control) fed with high fat diets (HFD) and the control group of obesity treatment were administered 20 mg / kg of orlistat To examine the effect of obesity treatment on obesity after oral administration of diluted orally administered control group (Orlistat), the extract of Lactobacillus casei Probio-65 culture liquid prepared in Example 2 was prepared by lyophilizing into powder, and the concentration of 50 mg / kg (SEL001 (50 mg / kg)), and Lactobacillus casei probiotypes (Lactobacillus casei) (live cells (10 ^ 8)) were divided into five experimental groups. Orlistat, a drug developed by Roche, is known to have the ability to inhibit local fat absorption.

4-4 Measurement of weight change after eating

The weight for each test group was measured for 10 weeks.

FIG. 7 is a graph showing changes in body weight for 10 weeks in a normal control, an HFD control, an obesity treatment control group (Orlistat), an obesity treatment group (SEL001), and a live cell group.

As shown in FIG. 7, the average weight of the first week was 42.08 g in the normal control, 43.305 g in the obesity control (HFD Control), 44.46 g in the obesity treatment control group (Orlistat) , And 41.68 g in the strain (Live cell). After 10 weeks of the experiment, the average body weight was significantly changed. The mean body weight was changed to 56.97g in normal control, 74.25g in obesity control (HFD Control), 65.35g in obese control group (Orlistat), 58.96g in obesity treatment group , And 49.29 g in the strain (Live cell). It is shown that the obesity treatment group (SEL001) and the live cell group according to the present invention have decreased body weight gain rate compared with the obesity control group (HFD Control) and have a lipid absorption inhibitory effect on the body against HFD administration.

FIG. 8 is a graph showing weight gain after 10 weeks of a normal control, an HFD control, an obesity treatment group (Orlistat), an obesity treatment group (SEL001), and a live cell group. As can be seen in FIG. 8, in relation to the weight gain after 10 weeks of the experiment, the normal control group was 14.89 g, the obesity control group (HFD control) was 30.95 g, the obese control group (Orlistat) was 20.88 g, (SEL001) and the live cell were 3.665 g, respectively. The obesity treatment group (SEL001) and the live cell group were superior to the obesity control group (Orlistat) It was confirmed that the live cells of the strains were significantly superior to the normal controls and had a remarkably superior anti-obesity effect.

After 10 weeks of breeding, mice fasted for 12 hours were anesthetized with ether and dissected. Blood was collected from the abdominal vein using a heparinized syringe. After blood collection, the blood was left for 30 minutes and centrifuged at 3,000 rpm for 15 minutes to separate plasma. The separated plasma was quenched with liquid nitrogen and stored at -80 ° C until analysis. Total cholesterol, triglyceride, high density lipoprotein (HDL) - cholesterol content (HDL) and LDL (low density lipoprotein) - cholesterol content (HDL) were analyzed using a blood analyzer .

FIG. 9 is a graph showing the oral administration effect of the extract of Lactobacillus casei Probio-65 on total cholesterol after 10 weeks of the experiment. As can be seen from FIG. 9, the total cholesterol levels (TC) were 141.53 mg / dL, 139.33 mg / dL and 145.76 mg / dL, respectively, in the obesity treatment control group (Orlistat), obesity treatment group (SEL001) dL, and 323.05 mg / dL for obesity control (HFD Control), respectively. This indicates that TC is increased by obesity induced by HFD. Treatment with obesity control group (Orlistat), obesity treatment group (SEL001) and strain treated group (Live cell) showed an anti-obesity effect which suppresses increase of TC.

 FIG. 10 is a graph showing the oral administration effect of an extract of Lactobacillus casei Probio-65 on triglyceride 10 weeks after the experiment. 10, Triglycereide (TG) was 0.54 nmol / L, 0.85 nmol / L and 1.11 nmol / L in the obese control group (Orlistat), obesity treatment group (SEL001) TG was 1.88 nmol / L in obesity control group (HFD Control). In addition, obesity treatment group (Orlistat) and obesity treatment group (SEL001) had lower TG than normal control group. This indicates that the obesity treatment control group (Orlistat) and the obesity treatment group (SEL001) have the effect of reducing the TG of HFD-induced obesity mice.

FIG. 11 is a graph showing the oral administration effect of extract of Lactobacillus casei Probio-65 on HDL-cholesterol content (HDL) 10 weeks after the experiment, and FIG. 12 is a graph showing the oral administration effect of LDL-cholesterol content A graph showing the oral administration effect of the extract of Lactobacillus casei Probio-65. As can be seen in Figures 11 and 12, high-density lipoprotein (HDL) was measured lower in the obesity control (HFD Control) than in the normal control (Normal Control). The HDL levels in the obese control group (Orlistat), obesity treatment group (SEL001) and the live cell group were 43.31 mg / dL, 46.52 mg / dL and 39.66 mg / dL, respectively. Obese treatment group (SEL001) showed higher effect than obese treatment control group (Orlistat) and strain group (Live cell). In addition, the amount of low-density lipoprotein (LDL) was higher in the obese control group (HFD Control) than in the normal control group (Normal Control). LDL levels were measured as 31.39 mg / dL, 45.76 mg / dL and 42.66 mg / dL in the obese control group (Orlistat), the obesity treatment group (SEL001) and the live cell group.

FIG. 13 is a graph showing the oral administration effect of the extract of Lactobacillus casei probi-65 on the leptin content, and FIG. 14 is a graph showing the oral administration effect of the extract of Lactobacillus casei Probio-65 on the adiponectin content FIG. 15 is a graph showing the oral administration effect of the extract of Lactobacillus casei Probio-65 on the content of ricin; FIG. 16 is a graph showing the oral administration effect of the extract of Lactobacillus casei Probio- FIG. 17 is a graph showing the oral administration effect of the extract of Lactobacillus casei-65 on the IL-6 content. FIG.

As shown in FIGS. 13 to 17, the amount of leptin was higher in the obesity control group (Orlistat), the obesity treatment group (SEL001) or the strain After treatment with live cells, the amount of leptin decreased. The expression level of adiponectin was decreased by more than 80% in the obese control group (HFD Control) compared to the normal control group. The amount of adiponectin after treatment with obesity treatment group (Orlistat), obesity treatment group (SEL001) or live cell group was 30 ~ 45% lower than that of normal control, but 30 ~ 45% lower than that of obesity control (HFD control) Respectively. The expression level of resistin was increased in the obesity control group (Orlistat), the obesity treatment group (SEL001) or the treatment group of the strain (Live cell) after the treatment of the obesity treatment group (SEL001) The expression level of stin was similar to that of normal control or decreased by more than 40% compared to that of normal control. The expression level of IL-1β was increased in obese control group (HFD Control) compared to normal control group (Orlistat), obesity treatment group (SEL001) or live cell group (HFD Control ) Than that of IL-1β. The expression level of IL-6 was increased by more than 200% in the obese control group (HFD Control) compared with the normal control group (Orlistat), obesity treatment group (SEL001) 6 expression level remained similar to that of the normal control (Normal Control) or decreased slightly.

Although the preferred embodiments of the present invention have been described, the present invention is not limited to the specific embodiments described above. It will be apparent to those skilled in the art that various modifications and variations can be made in the present invention without departing from the spirit or scope of the appended claims, And equivalents should also be considered to be within the scope of the present invention.

Claims (5)

1. A composition for preventing or treating diabetes and obesity comprising Lactobacillus casei Probio-65 as an active ingredient.
2. The composition for prevention or treatment of diabetes and obesity according to claim 1, wherein the Lactobacillus casei probi-65 is a Lactobacillus casei Probio-65 culture medium in which a Lactobacillus casei Probio-65 strain is liquid-cultured.
3. The method according to claim 1, wherein the Lactobacillus casei probi-65 is a powder cell obtained by removing Lactobacillus casei Probio-65 from a liquid culture of Lactobacillus casei Probio-65 strain by drying or spray drying A composition for preventing or treating diabetes and obesity.
4. The method according to claim 1, wherein the Lactobacillus casei probio-65 is obtained by extracting a Lactobacillus casei Probio-65 culture liquid in which a Lactobacillus casei Probio-65 strain has been liquid-cultured with a solvent, filtering the resultant, The present invention relates to a composition for preventing or treating diabetes and obesity.
5. The method according to claim 1, wherein the Lactobacillus casei probio-65 is obtained by extracting a Lactobacillus casei Probio-65 culture liquid in which a Lactobacillus casei Probio-65 strain has been liquid-cultured with a solvent, filtering the resultant, A composition for preventing or treating diabetes and obesity, which is a powder of Lactobacillus casei Probio-65 culture liquid obtained by removing the moisture by freeze-drying or spray-drying the culture liquid of Probio-65.

Images